Relay Therapeutics to Participate in Two Upcoming Investor Conferences in November

Group 1 - Relay Therapeutics, Inc. is a clinical-stage company focused on developing small molecule precision medicine for cancer and genetic diseases [2] - The company will participate in two upcoming fireside chats in November, which will be webcast live and available for replay for 30 days [1] - Relay's lead clinical asset, RLY-2608, is the first pan-mutant selective PI3Kα inhibitor in clinical development, currently in a Phase 3 trial for HR+/HER2- metastatic breast cancer [2] Group 2 - Relay's Dynamo platform utilizes advanced computational and experimental methods to target previously challenging protein targets [2] - The company is also exploring RLY-2608 for PI3Kα-driven vascular malformations and has late-stage research programs for NRAS-driven solid tumors and Fabry disease [2] - Upcoming events include Guggenheim's Healthcare Innovation Conference on November 10, 2025, and Jefferies Global Healthcare Conference on November 19, 2025 [3]